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Introduction
Thrombophilia is a condition that predisposes an individual to be more susceptible to develop thromboembolism. The well-established backgrounds of thrombophilia from genetic origin (genetic or hereditary thrombophilia [HT] ) are either increased pro-coagulant activity or hereditary deficiency of natural anticoagulants (NAs). 1, 2 The former includes activated protein C resistance (factor V Leiden mutation) and prothrombin G20210A mutation, both of which are restricted to Western populations. The latter condition includes deficiencies of protein C (PC), protein S (PS) and antithrombin (AT), and is the major culprit of thrombophilia in Asian populations. Of note, thrombophilia from NA deficiency confers higher risk of venous thromboembolism (VTE) than that from increased procoagulant activities. 3, 4 In particular, AT deficiency is the first genetic risk factor for VTE identified in human and confers the highest risk. 2, 4, 5 Thus, diverse genetic backgrounds are believed to be the major factor accounting for the different risk of VTE by ethnic origins. In addition, understanding of genotype-phenotype correlations and structure-function relationships by way of identifying the causative genetic defect is important for risk assessment in VTE patients and also in population. 6 Recently, there has been growing acknowledgement of the risk of VTE and the socioeconomic burden in Asian countries, facilitating the research on the genetic risk factors, accordingly. 7, 8 There have been several studies on the prevalence of genetic thrombophilia in Asia; however, the laboratory strategy to detect HT has varied across studies.
Before the wide availability of molecular genetic tests, the strategy was typically dependent on coagulation test results. Recent studies try to incorporate molecular genetic tests to confirm the coagulation defect by direct identification of causative mutations with or without screening by coagulation tests. This is particularly because the coagulation test results can be affected by a variety of factors such as underlying disease and medication, leading to false hereditary deficiency. 9 However, there still have been limited studies showing the prevalence and mutation spectrum of all 3 types of NAs, particularly simultaneously in both patients with VTE and in the general population in a given ethnicity.
In this regard, we investigated the molecular genetic defects of NA deficiencies (PC, PS, and AT)
in a large number of consecutive VTE patients and in general population in Korea screened by coagulation tests. The results revealed unique frequencies and mutation spectrums of NA deficiencies in the VTE patient and population groups not only distinct from Caucasian populations but also from other Asian countries.
Methods

Patients and population
The patient group consisted of consecutive VTE patients screened for thrombophilia including PC, 10 Tests for PC Ag, PS total Ag and activity, and AT Ag were additionally performed when indicated. NA deficiency was suspected in VTE patients when the result was below the lower limit of the reference interval (2.5-percentile). The screening of NA deficiency in the population group was performed by the same coagulation tests as in VTE patients. Those with decreased levels of PC, PS, or AT below 1-percentile were selected for molecular genetic tests.
Molecular genetic analyses
Genomic DNA was extracted from peripheral blood leukocytes using the Wizard Genomic DNA 
Results
NA deficiency and causative mutations in the patient group
Total 500 patients were diagnosed with VTE and were screened for thrombophilia during the study Figure 1A ). Seven patients (19.4%) had 2 (double) mutations ( Table 2) . Among the PROC mutations, 2 were novel (Arg264Gly and Gly266Arg) ( Table 1 and Figure 1A ). Two mutations were not observed in PROC, while they accounted for 14.3% and 18.2% in PROS1 and SERPINC1, respectively. All novel mutations had 0% population frequency. Among the 8 novel missense mutations, all mutated residues were highly conserved across species, and all mutations were predicted to be damaging except for Arg316His ( Table 1 and Supplementary Figures).
Among the 8 patients with double mutations, 4 patients were considered to have severe PC deficiency from compound heterozygous PROC mutations based on coagulation test results with or without family study ( Table 2) . None had double mutations or large dosage mutations on MLPA in the population group. In the population group, 1 novel mutation was detected in PROS1 (Ser587del), which had 0% of population frequency ( Table 1) . The mutation detection rates were 33.3% in PC deficiency (7/21), 15 .4% in PS deficiency (2/13), and 50% in AT deficiency (13/26 
NA deficiency and causative mutations in the population group
Discussion
In this study, we determined the frequencies and mutation spectrums of genetically confirmed NA deficiencies underlying genetic thrombophilia in Korea. The results demonstrated that AT deficiency is frequent both in VTE patients and in general population in Korea. In particular, the frequency of AT deficiency in the population group was highest (0.49%) compared with the results from previous population studies. 9, [12] [13] [14] [15] [16] In the patient group, the frequency of genetically confirmed NA deficiency was 14.2% (71/500). PC deficiency was most frequent (50.7%), followed by AT deficiency (29.6%) and PS deficiency (19.7%). Among the 43 PROC mutations in the patient group, 2 missense mutations, Arg211Trp and Met406Ile, accounted for more than half (53.5%) of all mutations ( Figure 1A) . In the corresponding population group, Arg211Trp was more predominant (accounting for 85.7%), while Met406Ile was not observed. Both Arg211Trp and Met406Ile (or Arg169Trp and Met364Ile) were first reported in Japanese patients with VTE and cause type I PC deficiency. 17, 18 Arg211Trp is a recurrent mutation occurring at a CpG hotspot at the alpha thrombin cleavage site of the heavy chain. It was reported to account for ~10% of PROC mutations in Japan and has also been described in Caucasian patients with VTE.
19-21 Met406IIle
1 0 occurs at a non-CpG site of the trypsin-like serine protease domain and has been described exclusively in Japan, accounting for ~8% of PROC mutations in Japanese VTE patients. 21 Thus, both Arg211Trp and Met406Ile of PROC are recurrent in Korea and Japan, but much enriched in Korea (32% and 21% in Korea vs 10% and 8% in Japan, respectively). The unusually high frequency of AT deficiency in our population group was due to 2 prevalent missense mutations, Arg79Cys and Ser148Pro of SERPINC1 ( Figure 1C) . By contrast, they were observed only in 3 in the patient group. Both Arg79Cys and Ser148Pro (or Arg47Cys and Ser116Pro), which were first described in Japan, result in loss of the heparin binding ability of the AT molecule and cause type
IIb deficiency (qualitative defect). 22, 23 Arg79Cys occurs at a CpG hotspot and has been reported to be recurrent, while Ser148Pro does not involve a CpG hotspot, and no other patient has been described to carry this mutation in the literature after the first report. 24 In AT, type II deficiency is further divided into 3 types based on the location of molecular defect, as IIa (thrombin-binding site), IIb (heparin-binding site), and IIc (pleiotropic). Among them, type IIb AT deficiency is known to be less thrombogenic and is less common in patients with VTE than in general population. 25 Our results that revealed a striking difference in the proportion of type IIb mutations between the patient and the population group (13.6% [3/22] vs 100% [13/13] , respectively) were in line with the previous observations. PS deficiency was least frequent both in patient and population groups in our study without any predominant mutations ( Figure 1B) . As for the population-specific prevalent mutations, frequent Lys196Glu (K196E) of PROS1 in Japan results in the highest frequency of PS deficiency both in VTE patients and in general population ( Table 3) . [26] [27] [28] Although the sensitivity of coagulation tests are limited in detecting heterozygous Lys196Glu mutation, 27, 29, 30 earlier studies involving only coagulation tests also demonstrated a high population frequency of PS deficiency in Japan. 14,15,31 Lys196Glu was not observed in our study or in other previous studies, indicating it is a unique mutation in Japan. In China, 2 recent studies reported 2 predominant mutations of PROC, Lys173del and Arg189Trp, both in VTE patients and in general population (Table 3) . 32, 33 Lys173del and Arg189Trp were observed in 3 and 1 patients in our study, respectively, but not in the population group ( Figure 1A) . Of note, all 3 patients with heterozygous
Lys173del also had another PROC mutation ( Table 2) . Since Lys173del does not result in a 1 significant decrease of the amidolytic activity of PC, it is plausible that any heterozygous carriers of Lys173del in the patient or population group would have been missed in this study. 33 The studies from Western countries have shown that PC deficiency is the most frequent NA deficiency in VTE patients, followed by PS and AT deficiency, with limited reports on predominant mutations. 2, 9 Ala416Ser (or Ala384Ser) of SERPINC1 (Antithrombin Cambridge II) was reported to be frequent both in VTE patients and in general population in Britain, while it was not detected in China. 34, 35 Collectively, the frequency and mutation spectrum underlying genetic thrombophilia were different among Asian countries due to the presence of population-specific prevalent mutations possibly from founder effects.
The frequency of genetically confirmed NA deficiency in consecutive (unselected) VTE patients of our series was 14.2%. The frequency of NA deficiency in VTE patients of Western ethnicity was reported to be ~8%. 2, 9 In Asian countries, the frequency had been reported 28.3% in Japan by coagulation tests, which was similar to 25.4% with suspected NA deficiency in our study. 14 In a recent study by Miyata et al., in which NA deficiency was detected by molecular genetic analyses without screening by coagulation tests, 32% of VTE patients had genetically confirmed NA deficiency. 28 In addition to the presence of prevalent Lys196Glu of PROS1 in Japan, they discussed that the high frequency would have been due to a selection bias in patient recruitment that had possibly enriched those with NA deficiency in their study patients. Likewise, the 14.4% frequency in the present study was lower than the frequency of 24.1% in our previous study on selected (idiopathic) patients with pulmonary embolism. 36 The population frequencies of NA deficiency in Western ethnic populations have been described as PC deficiency at 0.2-0.45%, PS deficiency at 0.03-1.3%, and AT deficiency at 0.02-0.25%. 9, [37] [38] [39] [40] [41] [42] The differences in the methodological strategy to screen and confirm the deficiency (e.g., type/frequency of tests, family study, and cutoffs) could have affected the figures. In particular, earlier studies involved only coagulation tests, while recent studies tend to involve molecular genetic tests to confirm the hereditary nature of deficiency.
Molecular genetic tests are critical not only to rule out transient or acquired deficiency but also to understand the structure-function relationship and precise molecular pathophysiology (particularly relevant to thrombotic risk assessment in AT deficiency). For example, a same research group assessed the population frequency of AT deficiency, and the frequency was decreased from 0.25% by only coagulation tests to 0.17% by further molecular genetic confirmation. 12, 13 In our study, we first screened NA deficiency by a panel of PC activity, PS free Ag, and AT activity, which are recommended to be the 1 st screening assays with high sensitivity and reproducibility, and low interference, despite the limitations in certain rare types of mutant molecules. [43] [44] [45] Then we selected individuals with a value <1-percentile for molecular genetic tests. For PS and AT deficiency, we additionally performed MLPA experiments when no point mutations were detected on direct sequencing analyses, considering the significant occurrence of large dosage mutations in PROS1
and SERPINC1. 11 Thus, the figures we obtained were conservative estimations of population frequencies of NA deficiency. A recent study from China adopted the same strategy as in our study (<1-percentile of coagulation tests followed by molecular confirmation) on 3,493 individuals from the general population, and obtained frequencies of NA deficiency at 0.43% (PC deficiency 0.29%, AT deficiency 0.086%, and PS deficiency 0.057%) without any prevalent mutations ( Table 3) . 16 Thus, our findings of a population frequency of ~1.0% of NA deficiency and ~0.49% of AT deficiency with 3 recurrent missense mutations (Arg211Trp of PROC and Arg79Cys and Ser148Pro of SERPINC1) are distinct from previous studies from Asian countries as well as those from Western populations.
The mutation detection rate for confirmation of NA deficiency in our study was 55.9% (71/127) in the patient group and was 36.7% (22/60) in the population group. In both groups, the rate was highest in SERPINC1 (75% and 50% in patients and in population, respectively), followed by PROC (55.9% and 36.7%) and PROS1 (37.8% and 15.4%). The overall mutation detection rate (3 genes combined) and the order were similar to those recently reported in a large patient cohort from Germany (overall 65.8% with SERPINC1 84%, PROC 69.2%, and PROS1 43.2%). 46 The overall mutation detection rate in the population group in our study was lower than that in the patient group (36.7% vs 56.7%), but was higher than 15.8% recently reported in a population study by Zhu et al in China.
3
highest mutation detection rate in PROC (31.3%), followed by SERPINC1 (9.7%) and PROS1 (6.3%). This striking difference was in part due to the presence of 2 prevalent missense mutations (Arg79Cys and Ser148Pro) in the Korean population. Interestingly, however, 2 of 3 SERPINC1 mutations in the Chinese population were also Arg79Cys and Ser148Pro each. Large dosage mutations were frequent in AT deficiency and PS deficiency in our patient group (18.2% in SERPINC1 and 14.3% in PROS1) (Figure 2) , and they were more frequent than in previous studies (9.1% and 6.4%, respectively). 47 , 48 Although we did not perform MLPA experiments for PROC, the number of cases with large dosage mutations causing PC deficiency would have been quite limited when considering the rare occurrence of those mutations in PROC (0.6%). 47, 48 None had large dosage mutations in the population group. Total 16 novel mutations were identified in this study, 2
in PROC, 7 in PROS1, and 7 in SERPINC1 ( Table 1) . 48 The large duplication mutation involving all exons (1 through 7) of SERPINC1 was detected in Patient SMC-Pt-AT16 with type I AT deficiency. We could not delineate the extent of the duplicated genomic segment in the case, but it could be large enough to involve a significant extragenic region. 11 Eight patients had double mutations (7 with PC deficiency and 1 with AT deficiency) ( Table 2 ). Among 7 patients with 2 PROC mutations, 4 patients were considered to have compound heterozygous mutations (severe PC deficiency) based on coagulation test results (PC activity 2-7%) with or without family study (SMC-Pt-PC10, 11, 21, and 36). Three patients had Lys193del plus a missense mutation (SMC-Pt-PC14, 18, and 27). Although the PC activities of these 3 patients were 41-62%, the phase of the 2 mutations could not be inferred without testing their parents because of the minimal decrease of the amidolytic activity of PC in Lys193del carriers. 33 The 2 SERPINC1 mutations in Patient SMC-Pt-AT21 were inferred to be on the same allele (cis) considering the AT activity of 43%. Of note, the mean age of onset of disease in 4 patients with severe deficiency from compound heterozygous mutations was younger than that in the other 4 patients (23 vs 39 years). Collectively, the proportion of severe deficiency in our patient series was estimated to be 11% for PC deficiency and 0% for both PS and AT deficiency. 
